About Altanova

Michael W. Porter

More than twenty-five years building, acquiring and scaling regulated healthcare and specialty pharmaceutical platforms across the United States, Europe and international markets. Michael W. Porter is Founder and Executive Chairman of Altanova Pharma Group AG in Zug, Switzerland, where he leads corporate strategy, governance, platform architecture and strategic partnerships. He co-founded Covis Pharma Group and served as its Chief Executive Officer, building the company into a top-ten global respiratory pharmaceutical platform with more than US$600 million in annual sales, more than 300 employees and commercial operations across more than 55 countries, while completing 23 M&A transactions. The Covis platform generated more than US$1.5 billion in distributed profit for its institutional sponsors across three monetization events. Across his career, he has led more than 25 life-sciences M&A and strategic transactions. Michael is Co-Founder and Managing Partner of PG Equity Group, the family office through which he and Liliana Gómez invest as operating partners in regulated healthcare, technology and critical-minerals businesses. He also serves as Independent Director and Audit Committee Chair of Freedom Metals Acquisition Corp., a Nasdaq-listed company, and as a director of restor3d, Pressio Spine and Huxley Medical, including Audit Committee Chair responsibilities at restor3d and Pressio Spine. He holds an MBA from Columbia Business School with a concentration in Finance and International Business.

Dr. Raghav Chari

Thirty years in biopharmaceutical research, development and commercialisation across neurology, oncology, inflammation, metabolic disease and dermatology. Dr. Raghav Chari advises Altanova on portfolio selection, formulation strategy and development planning. He currently serves as Chief Science Officer of Azurity Pharmaceuticals, where he is responsible for scientific strategy and development of the company's clinical pipeline. He previously served as Chief Innovation Officer of Covis Pharma, where he led research and development, and held senior leadership roles at Dr. Reddy's Laboratories and Promius Pharma. His expertise centres on 505(b)(2) and hybrid-medicine development, integrating formulation science, modelling, clinical pharmacology and late-stage development. Raghav began his career at McKinsey & Company, advising biopharmaceutical clients on strategy, licensing and M&A. He has contributed to more than 50 licensing, product-development and corporate transactions and has co-founded biotechnology companies working at the intersection of drug discovery and artificial intelligence. He holds a PhD in Physics from Princeton University and a BSc in Mathematics from the California Institute of Technology.

Ozgur Kilic

More than twenty years in finance, operations and strategy across global pharmaceutical companies and private equity-backed businesses in Europe and the United States. Ozgur Kilic advises Altanova on financial architecture, operating cadence, organisational design and corporate development. He is an experienced global business executive and board director who has served in Chief Executive Officer, Chief Financial Officer and Chief Operating Officer roles across global public companies and private equity-backed pharmaceutical businesses, including as Chief Financial Officer and Chief Operating Officer of Covis Pharma. He currently serves as a director of Avicanna Inc., a publicly listed international biopharmaceutical company. His career spans roles in Switzerland, the United Kingdom, Italy, Germany and the United States, with industry experience across branded pharmaceuticals, oncology, generics and biosimilars, vaccines, eye care, consumer health and medical devices. His functional expertise covers commercial operations, manufacturing, research and development, corporate finance and transactions. He holds degrees in Business Administration and History from Koç University and an MBA in Finance and Investment from the Stuttgart Institute of Management and Technology. He is an Associate Chartered Management Accountant and Chartered Global Management Accountant and has completed executive education at Harvard Business School.